Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 4.37 · gapped above the open, then crossed back over prior close. High/low 5.35 at 7:45 am ET, 4.28 at 4:45 pm ET.
Armata Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Biological Products, (No Diagnostic Substances)
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On December 1, 2025, we entered into a Capital on Demand™ Sales Agreement (the "Sales Agreement") with JonesTrading Institutional Services LLC ("Jones"), relating to the offer and sale of shares of its common stock.”
FILING10-K0001104659-26-034532cik 0000921114
“On August 11, 2025, we entered into a credit and security agreement (the "August 2025 Credit Agreement") for a loan in the aggregate amount of $15.0 million (the "August 2025 Loan") with Innoviva Sub.”
FILING10-K0001104659-26-034532cik 0000921114
“This study was supported by the CFF, which granted us a Therapeutics Development Award of $5.0 million.”
FILING10-K0001104659-26-034532cik 0000921114
“On June 15, 2020, we entered into an agreement with the Medical Technology Enterprise Consortium ("MTEC Agreement"), pursuant to which we received a $15.0 million award and have entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.”
FILING10-K0001104659-26-034532cik 0000921114
“On June 15, 2020, we entered into an agreement with the Medical Technology Enterprise Consortium ("MTEC Agreement"), pursuant to which we received a $15.0 million award and have entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.”
FILING10-K0001104659-26-034532cik 0000921114
“On June 15, 2020, we entered into an agreement with the Medical Technology Enterprise Consortium ("MTEC Agreement"), pursuant to which we received a $15.0 million award and have entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.”
FILING10-K0001104659-26-034532cik 0000921114
“On June 15, 2020, we entered into an agreement with the Medical Technology Enterprise Consortium ("MTEC Agreement"), pursuant to which we received a $15.0 million award and have entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.”
FILING10-K0001104659-26-034532cik 0000921114
“On June 15, 2020, we entered into an agreement with the Medical Technology Enterprise Consortium ("MTEC Agreement"), pursuant to which we received a $15.0 million award and have entered into a multi-year program administered by the U.S Department of Defense through MTEC and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.”
FILING10-K0001104659-26-034532cik 0000921114
“We completed an investigator-sponsored clinical trial of AP-SA01 at the University of Adelaide in Australia for CRS in December 2016.”
FILING10-K0001104659-26-034532cik 0000921114
“On June 15, 2020, we entered into an agreement (the "MTEC Agreement") with the Medical Technology Enterprise Consortium ("MTEC"), pursuant to which we received a $15.0 million award and entered into a multi-year program administered by the U.S. Department of Defense (the "DoD") through MTEC and managed by the Naval Medical Research Command – Naval Advanced Medical Development with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.”
FILING10-K0001104659-26-034532cik 0000921114
“On June 15, 2020, we entered into an agreement (the "MTEC Agreement") with the Medical Technology Enterprise Consortium ("MTEC"), pursuant to which we received a $15.0 million award and entered into a multi-year program administered by the U.S. Department of Defense (the "DoD") through MTEC and managed by the Naval Medical Research Command – Naval Advanced Medical Development with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.”
FILING10-K0001104659-26-034532cik 0000921114
“In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $100,000,000 from time to time subject to certain conditions, through or to Jones, acting as agent or principal.”
FILING10-K0001104659-26-034532cik 0000921114
Watchlist prices, news filtered to it, and its next report on your desk.
Armata Pharmaceuticals, Inc. has 11 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Armata Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
ARMP (Armata Pharmaceuticals, Inc.) has 11 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: INVA −0.32%, in healthcare.